含原诱导缓解方案与多种不同方案强化治疗急性髓细胞白血病的疗效观察-东南大学学报医学版

含原诱导缓解方案与多种不同方案强化治疗急性髓细胞白血病的疗效观察

单位：安徽省蚌埠市第三人民医院血液科, 安徽蚌埠 233000

分类号：R733.71; R730.53

出版年·卷·期（页码）：2009·28·第三期（232-234）

摘要：

目的: 探讨急性髓系白血病(AML)诱导缓解后的适宜强化治疗方案。方法: 37例AML患者随机分成原方案组和多种方案组,除复发者外,均强化治疗1~2年。原方案组采用原诱导缓解方案(DA或MA)、原诱导缓解方案联合依托泊苷或替尼泊苷或高三尖杉酯碱、原诱导缓解方案中的阿糖胞苷由常规剂量改为中或大剂量等方案进行交替化疗;多种方案组采用中或大剂量阿糖胞苷、HA、HAE、DA、DAE、MA、MAE、AA等方案交替应用,其中原诱导缓解方案应用2~3个疗程。结果: 原方案组和多种方案组患者 1年无病生存(DFS)率分别为76.5%和70%(P >0.05),3年DFS率分别为46.7%和12.5%(P <0.05)。结论: 采用含诱导缓解方案的方法反复强化治疗AML,远期疗效优于多种不同方案交替治疗的方案。

Objective To explore the suitable consolidation therapy strategy of the acute myelogenous leukemia (AML) after complete cytomorphological remission (CR).Method Patients in complete remission were randomized for two cycles of consolidation therapy: the induction regimen group and the multi-regimen group.The former included the original induction regimen,the original induction regimen plus etoposide,teniposide or homoharringtonine.The routine dosage of cytarabine in the original induction regimen was changed into middle or large dosage.The latter contain middle or large dosage of cytarabine,HA,HAE,DA,DAE,MA,MAE,AA et al,including 2~3 course of original induction regimen.Result In the induction regimen group and multi-regimen group,the patients' disease free survival (DFS) was 76.5% and 70%(P >0.05) at 1 years and 46.7% and 12.5%(P <0.05) at 3 years respectively.Conclusion Repeated intensification therapy including the induction regimen for AML can result in better efficacy than the alternate of multi-regimen.

参考文献：

[1] FIEGL M,HIDDEMANN W,BRESS J.Current therapeutic strategies in the management of acute myeloid leukemia[J].Med Klin(Munich),2007,102(4):309-316.
[2] VOGLER W R,WEINEER R S,MOORE J O,et al.Long-term follow-up of a randomized post-induction therapy trial in acte myelogenous leukemia(A Southeastern Cancer Study Group Trial)[J].Leukemia,1995,9:1456-1460.
[3] BOHM A,PINBAUER M,WIMAZAL F,et al.High dose intermittent Ara-c(HiDAC) for consolidation of patients with de nove AML:a single ceter experience[J].Leuk Res,2005,29(6):609-615.
[4] KERN W,ESTEY E H.High-dose cytosine arabinoside in the treatment of acute myeloid leukemia[J].Cancer,2006,107:116-124.
[5] 虞咏知,黄知平,董莉,等.急性非淋巴细胞白血病中剂量阿糖胞苷巩固强化治疗的临床观察[J].临床血液学杂志,2006,19(4):241.
[6] KENNETH F,BRADSTOCK J P,MATTHEWS R M,et al.A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine[J].Blood,2005,105:481-488.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录